The Experts below are selected from a list of 114 Experts worldwide ranked by ideXlab platform
Vincent P Houser - One of the best experts on this subject based on the ideXlab platform.
-
Fluvoxamine Maleate in the treatment of depression a single center double blind placebo controlled comparison with imipramine in outpatients
Journal of Clinical Psychopharmacology, 1996Co-Authors: James L Claghorn, Craig Q Earl, Donna D Walczak, Kim A Stoner, Lung Fai Wong, Donald R Kanter, Vincent P HouserAbstract:The efficacy and safety of Fluvoxamine Maleate, a selective serotonin reuptake inhibitor, was compared with placebo and imipramine in patients with major depressive disorder. Previous literature has cited a dose range of 100 to 300 mg/day of Fluvoxamine Maleate for the treatment of major depression; however, this study demonstrates that a dose range of 50 to 150 mg/day is as effective as imipramine (80-240 mg/day). After a 1- to 2-week, single-blind, placebo washout phase, 150 depressed outpatients were randomized to double-blind treatment with Fluvoxamine Maleate (50-150 mg/day), imipramine (80-240 mg/day), or placebo for 6 weeks. Fluvoxamine produced a significant therapeutic benefit over placebo (p < or = 0.05) as assessed by the total score on the Hamilton Rating Scale for Depression; imipramine (80-240 mg/day) produced similar results. The secondary outcome variables (i.e., Clinical Global Impression severity of illness item and 56-Item Hopkins Symptom Checklist depression factor) also showed significant differences between Fluvoxamine Maleate and placebo during three of the four final weeks of the study. Both Fluvoxamine Maleate and imipramine appeared to be safe and well tolerated by the majority of patients. As expected from the pharmacology of these agents, the imipramine groups reported more anticholinergic effects (dry mouth, dizziness, and urinary retention) and electrocardiographic effects, whereas the Fluvoxamine group reported more nausea, somnolence, and abnormal ejaculation. The majority of these adverse events were mild to moderate and, with the exception of dry mouth (imipramine) and abnormal ejaculation (Fluvoxamine), were transient. The data clearly demonstrate the antidepressant activity and tolerability of Fluvoxamine Maleate (50-150 mg/day) as compared with placebo; it is also as effective as the tricyclic antidepressant imipramine (80-240 mg/day) in patients with major depressive disorder.
Musa V Mabandla - One of the best experts on this subject based on the ideXlab platform.
-
Early Life Stress, Depression And Parkinson’s Disease: A New Approach
BMC, 2018Co-Authors: Ernest Dalle, Musa V MabandlaAbstract:Abstract This review aims to shed light on the relationship that involves exposure to early life stress, depression and Parkinson’s disease (PD). A systematic literature search was conducted in Pubmed, MEDLINE, EBSCOHost and Google Scholar and relevant data were submitted to a meta-analysis. Early life stress may contribute to the development of depression and patients with depression are at risk of developing PD later in life. Depression is a common non-motor symptom preceding motor symptoms in PD. Stimulation of regions contiguous to the substantia nigra as well as dopamine (DA) agonists have been shown to be able to attenuate depression. Therefore, since PD causes depletion of dopaminergic neurons in the substantia nigra, depression, rather than being just a simple mood disorder, may be part of the pathophysiological process that leads to PD. It is plausible that the mesocortical and mesolimbic dopaminergic pathways that mediate mood, emotion, and/or cognitive function may also play a key role in depression associated with PD. Here, we propose that a medication designed to address a deficiency in serotonin is more likely to influence motor symptoms of PD associated with depression. This review highlights the effects of an antidepressant, Fluvoxamine Maleate, in an animal model that combines depressive-like symptoms and Parkinsonism
-
Fluvoxamine Maleate effects on dopamine signaling in the prefrontal cortex of stressed parkinsonian rats implications for learning and memory
Brain Research Bulletin, 2017Co-Authors: Ernest Dalle, Willie M U Daniels, Musa V MabandlaAbstract:Parkinson's disease (PD) is also associated with cognitive impairment and reduced extrinsic supply of dopamine (DA) to the prefrontal cortex (PFC). In the present study, we looked at whether exposure to early life stress reduces DA and serotonin (5-HT) concentration in the PFC thus leading to enhanced cognitive impairment in a Parkinsonian rat model. Maternal separation was the stressor used to develop an animal model for early life stress that has chronic effects on brain and behavior. Sprague-Dawley rats were treated with the antidepressant Fluvoxamine Maleate (FM) prior to a unilateral 6-hydroxydopamine (6-OHDA) lesion to model motor deficits in rats. The Morris water maze (MWM) and the forelimb use asymmetry (cylinder) tests were used to assess learning and memory impairment and motor deficits respectively. Blood plasma was used to measure corticosterone concentration and prefrontal tissue was collected for lipid peroxidation, DA, and 5-HT analysis. Our results show that animals exposed to early life stress displayed learning and memory impairment as well as elevated basal plasma corticosterone concentration which were attenuated by treatment with FM. A 6-OHDA lesion effect was evidenced by impairment in the cylinder test as well as decreased DA and 5-HT concentration in the PFC. These effects were attenuated by FM treatment resulting in higher DA concentration in the PFC of treated animals than in non-treated animals. This study suggests that DA and 5-HT signaling in the PFC are responsive to FM and may reduce stress-induced cognitive impairment in PD.
-
Fluvoxamine Maleate normalizes striatal neuronal inflammatory cytokine activity in a parkinsonian rat model associated with depression
Behavioural Brain Research, 2017Co-Authors: Ernest Dalle, Willie M U Daniels, Musa V MabandlaAbstract:Abstract Cytokine dysfunction is associated with both depression and Parkinson’s disease (PD) pathophysiology. Inflammatory cytokines in neural and behavioral processes are involved in the production and/or maintenance of depression in PD. In this study we looked at how Fluvoxamine treatment regulates depressive-like signs, motor impairments and the expression of IL-1β, IL-6, TNF-α, TGF-β and IL-10 cytokines in the striatum of a stressed Parkinsonian rat model. Early maternal separation was used to model stress and depressive-like signs in rats. Maternally separated adult rats were treated with Fluvoxamine for 30 days prior to 6-hydroxydopamine (6-OHDA) lesion. The sucrose preference test (SPT) and the limb-use asymmetry test (cylinder test) were used to evaluate anhedonia and motor impairments respectively. Lipid peroxidation and cytokine expression were measured in striatal tissue using ELISA and real-time PCR techniques respectively. Our results show that maternal separation resulted in anhedonia and exacerbated 6-OHDA lesion but Fluvoxamine treatment attenuated these effects. Lipid peroxidation, mRNA levels of IL-1β, IL-6 and TNF-α were down-regulated while IL-10 and TGF-β levels were up-regulated in the lesioned striatum of Fluvoxamine treated rats. This study shows that early treatment with Fluvoxamine may attenuate inflammation on injured striatal neurons by favoring anti-inflammatory cytokine expression while decreasing pro-inflammatory cytokine release in the brain. This suggests a role of Fluvoxamine as a potential therapeutic intervention targeting neuronal inflammation associated with PD.
-
anti parkinsonian effects of Fluvoxamine Maleate in maternally separated rats
International Journal of Developmental Neuroscience, 2016Co-Authors: Ernest Dalle, Willie M U Daniels, Musa V MabandlaAbstract:Exposure to early life stress has been shown to result in anxiety-like symptoms and exacerbates degeneration of dopaminergic neurons in a rat model of Parkinson's disease (PD). First line treatment for anxiety disorders includes the use of Fluvoxamine Maleate (FM). In this study, we investigated whether treating anxiety-like symptoms with FM has an effect in alleviating the neurotoxic effects of 6-OHDA in a parkinsonian rat model. Early maternal separation was used to create a rat model that depicts anxiety-like symptoms. Maternally separated adult Sprague-Dawley rats were treated with FM prior to and following lesion with 6-hydroxydopamine (6-OHDA). The elevated plus-maze (EPM) and the forelimb akinesia tests were used to evaluate anxiety-like symptoms and motor impairment respectively. Blood plasma was used to measure corticosterone concentration, and striatal tissue was collected for dopamine (DA) and serotonin (5-HT) analysis. Our results show that animals exposed to early life stress displayed increased anxiety-like symptoms and elevated basal plasma corticosterone concentration which were attenuated by treatment with FM. A 6-OHDA lesion effect was evidenced by impairment in the forelimb akinesia test as well as decreased DA and 5-HT concentrations in the lesioned striatum. These effects were attenuated on DA neurons by FM treatment in the pre-lesion treated as opposed to the post-lesion treated rats. This study suggests that early treatment of anxiety-like behavior decreases the vulnerability of DA neurons to neurotoxic insults later in life thus slowing down DA degeneration in PD.
Lawrence H Price - One of the best experts on this subject based on the ideXlab platform.
-
a double blind placebo controlled study of Fluvoxamine in adults with autistic disorder
Archives of General Psychiatry, 1996Co-Authors: Christopher J Mcdougle, Susan T Naylor, Donald J Cohen, Fred R Volkmar, George R Heninger, Lawrence H PriceAbstract:Background: Autistic disorder is characterized by a fundamental disturbance in social interaction, impairments in communication, and a markedly restricted repertoire of activities and interests. Abnormalities in the serotonin neurotransmitter system have been identified in some persons with autism. No consistently effective and safe drugs have been developed for treating the symptoms of autism. Methods: Thirty adults with autistic disorder completed a 12-week double-blind, placebo-controlled trial of the potent and selective serotonin uptake inhibitor Fluvoxamine Maleate. Behavioral ratings were obtained at baseline and after 4, 8, and 12 weeks of treatment. Results: Eight (53%) of 15 patients in the Fluvoxamine-treated group were categorized as responders compared with none of 15 in the placebo group ( P =.001). Fluvoxamine was superior to placebo in reducing repetitive thoughts and behavior ( P P P P P Conclusions: Fluvoxamine is more effective than placebo in the short-term treatment of the symptoms of autistic disorder in adults. Controlled studies of Fluvoxamine and other potent and selective serotonin uptake inhibitors seem warranted in children and adolescents with autism.
W U Fanhong - One of the best experts on this subject based on the ideXlab platform.
-
synthesis of a new antidepressant Fluvoxamine Maleate
Chinese Journal of Medicinal Chemistry, 2004Co-Authors: W U FanhongAbstract:Aim To study on the synthesis of Fluvoxamine Maleate.Methods Fluvoxamine Maleate was synthesized using ethyl benzoate as the starting material via four steps,such as substitution reaction,aminolysis,hydrolysis and salt formation,etc..Results and Conclusions The target compound was identified by spectroscopic analysis,and the overall yield was 51%.The preparative method of N-(2-bromoethyl) phthalimide (4) is improved.
James L Claghorn - One of the best experts on this subject based on the ideXlab platform.
-
Fluvoxamine Maleate in the treatment of depression a single center double blind placebo controlled comparison with imipramine in outpatients
Journal of Clinical Psychopharmacology, 1996Co-Authors: James L Claghorn, Craig Q Earl, Donna D Walczak, Kim A Stoner, Lung Fai Wong, Donald R Kanter, Vincent P HouserAbstract:The efficacy and safety of Fluvoxamine Maleate, a selective serotonin reuptake inhibitor, was compared with placebo and imipramine in patients with major depressive disorder. Previous literature has cited a dose range of 100 to 300 mg/day of Fluvoxamine Maleate for the treatment of major depression; however, this study demonstrates that a dose range of 50 to 150 mg/day is as effective as imipramine (80-240 mg/day). After a 1- to 2-week, single-blind, placebo washout phase, 150 depressed outpatients were randomized to double-blind treatment with Fluvoxamine Maleate (50-150 mg/day), imipramine (80-240 mg/day), or placebo for 6 weeks. Fluvoxamine produced a significant therapeutic benefit over placebo (p < or = 0.05) as assessed by the total score on the Hamilton Rating Scale for Depression; imipramine (80-240 mg/day) produced similar results. The secondary outcome variables (i.e., Clinical Global Impression severity of illness item and 56-Item Hopkins Symptom Checklist depression factor) also showed significant differences between Fluvoxamine Maleate and placebo during three of the four final weeks of the study. Both Fluvoxamine Maleate and imipramine appeared to be safe and well tolerated by the majority of patients. As expected from the pharmacology of these agents, the imipramine groups reported more anticholinergic effects (dry mouth, dizziness, and urinary retention) and electrocardiographic effects, whereas the Fluvoxamine group reported more nausea, somnolence, and abnormal ejaculation. The majority of these adverse events were mild to moderate and, with the exception of dry mouth (imipramine) and abnormal ejaculation (Fluvoxamine), were transient. The data clearly demonstrate the antidepressant activity and tolerability of Fluvoxamine Maleate (50-150 mg/day) as compared with placebo; it is also as effective as the tricyclic antidepressant imipramine (80-240 mg/day) in patients with major depressive disorder.